Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Renato Mantegazza, Fanny L O'Brien, Marcus Yountz, James F Howard Jr, REGAIN study group

Abstract

Objective: To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups.

Methods: Patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1 to receive either placebo or eculizumab during the REGAIN study (NCT01997229). Patients who completed REGAIN were eligible to continue into the open-label extension trial (NCT02301624) for up to 4 years. The four domain scores of each of the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale recorded throughout REGAIN and through 130 weeks of the open-label extension were analyzed.

Results: Of the 125 patients who participated in REGAIN, 117 enrolled in the open-label extension; 61 had received placebo and 56 had received eculizumab during REGAIN. Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment. These improvements were sustained through 130 weeks of the open-label extension.

Interpretation: Eculizumab treatment elicits rapid and sustained improvements in muscle strength across ocular, bulbar, respiratory, and limb/gross motor muscle groups and in associated daily activities in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.

Conflict of interest statement

R.M. and J.F.H. have received research support, honoraria, and nonfinancial support from Alexion Pharmaceuticals, which owns patent rights to eculizumab that was used in this study. F.L.O'B. and M.Y. are employed by, and own stock in, Alexion Pharmaceuticals, which owns patent rights to eculizumab that was used in this study.

© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Figures

Figure 1
Figure 1
Patient disposition through January 2019. In total, 117 patients were enrolled in the OLE; 56 had received eculizumab and 61 had received placebo during REGAIN. At OLE study end, 30 patients in total had discontinued (23.2% of the eculizumab/eculizumab group [13/56] and 27.9% of the placebo/eculizumab group [17/61]), and 87 patients had completed the study (76.8% of the eculizumab/eculizumab group [43/56] and 72.1% of the placebo/eculizumab group [44/61]). OLE = open‐label extension. Figure reproduced with permission from Vissing J, Jacob S, Fujita KP, et al. ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody‐positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 2020. (https://creativecommons.org/licenses/by/4.0/).
Figure 2
Figure 2
Changes in (A) MG‐ADL mean total score and (B) QMG mean total score from REGAIN baseline to OLE week 130. Patient numbers were not the same for each assessment. BL = baseline; CI = confidence interval; MG‐ADL = myasthenia gravis activities of daily living profile; OLE = open‐label extension; QMG = quantitative myasthenia gravis scale.
Figure 3
Figure 3
Changes in (A) MG‐ADL LS mean total score and (B) QMG LS mean total score from open‐label baseline to week 130. ‡P ≤ 0.001 compared with open‐label extension baseline, repeated‐measures analysis. Patient numbers were not the same for each assessment. Stable scores in the eculizumab/eculizumab group are evidence of maintained improvement achieved during eculizumab treatment in REGAIN in these patients. BL = baseline; CI = confidence interval; LS = least‐squares; MG‐ADL = myasthenia gravis activities of daily living profile; QMG = quantitative myasthenia gravis scale.
Figure 4
Figure 4
Correlations between MG‐ADL and QMG total scores (A) for changes from eculizumab baseline to last OLE assessment and (B) at last OLE assessment. Pearson’s correlation coefficients (R) were calculated for each treatment group. Each regression line was determined by a simple linear regression model of (A) change in MG‐ADL total score from REGAIN baseline to last OLE assessment against change in QMG total score from eculizumab baseline to last OLE assessment or (B) MG‐ADL total score at last OLE assessment as the response variable against QMG total score at last OLE assessment as the predictor variable for respective treatment groups, and its 95% confidence band was determined by the pointwise 95% confidence band. MG‐ADL = myasthenia gravis activities of daily living profile; OLE = open‐label extension; QMG = quantitative myasthenia gravis scale.
Figure 5
Figure 5
Changes in MG‐ADL mean domain scores from REGAIN baseline to OLE week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D) limb domains. Patient numbers were not the same for each assessment. Data are from patients with abnormal domain scores at REGAIN baseline only. BL = baseline; CI = confidence interval; MG‐ADL = myasthenia gravis activities of daily living profile; OLE = open‐label extension.
Figure 6
Figure 6
Changes in MG‐ADL LS mean domain scores from open‐label baseline to week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D) limb domains. *P ≤ 0.05, †P ≤ 0.01, ‡P ≤ 0.001 compared with open‐label baseline, repeated‐measures analysis. Patient numbers were not the same for each assessment. Stable scores in the eculizumab/eculizumab group are evidence of maintained improvement achieved during eculizumab treatment in REGAIN in these patients. Data are from patients with abnormal domain scores at REGAIN baseline only. BL = baseline; CI = confidence interval; LS = least‐squares; MG‐ADL = myasthenia gravis activities of daily living profile.
Figure 7
Figure 7
Changes in QMG mean domain scores from REGAIN baseline to OLE week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D) gross motor domains. Patient numbers were not the same for each assessment. Data are from patients with abnormal domain scores at REGAIN baseline only. BL = baseline; CI = confidence interval; OLE = open‐label extension; QMG = quantitative myasthenia gravis scale.
Figure 8
Figure 8
Changes in QMG LS mean domain scores from open‐label baseline to week 130 for (A) ocular, (B) bulbar, (C) respiratory, and (D) gross motor domains. *P ≤ 0.05, †P ≤ 0.01, ‡P ≤ 0.001 compared with open‐label baseline, repeated‐measures analysis. Patient numbers were not the same for each assessment. Stable scores in the eculizumab/eculizumab group are evidence of maintained improvement achieved during eculizumab treatment in REGAIN in these patients. Data are from patients with abnormal domain scores at REGAIN baseline only. BL = baseline; CI = confidence interval; LS = least‐squares; QMG = quantitative myasthenia gravis scale.

References

    1. Engel‐Nitz NM, Boscoe AN, Wolbeck R, et al. Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve 2018;58:99–105.
    1. Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054–1059.
    1. Mantegazza R, Pareyson D, Baggi F, et al. Anti AChR antibody: relevance to diagnosis and clinical aspects of myasthenia gravis. Ital J Neurol Sci 1988;9:141–145.
    1. Oh SJ, Kim DE, Kuruoglu R, et al. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992;15:720–724.
    1. Somnier FE. Clinical implementation of anti‐acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1993;56:496–504.
    1. Vincent A, McConville J, Farrugia ME, et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003;998:324–335.
    1. Vincent A, Newsom‐Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246–1252.
    1. Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141–149.
    1. Robertson NP, Deans J, Compston DA. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998;65:492–496.
    1. Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med 2013;86:255–260.
    1. Nowak RJ, Dicapua DB, Zebardast N, et al. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011;4:259–266.
    1. Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high‐dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 2008;1132:305–314.
    1. Silvestri NJ, Wolfe GI. Treatment‐refractory myasthenia gravis. J Clin Neuromuscul Dis 2014;15:167–178.
    1. Buzzard KA, Meyer NJ, Hardy TA, et al. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve 2015;52:204–210.
    1. Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti‐acetylcholine receptor antibody‐positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double‐blind, placebo‐controlled, multicentre study. Lancet Neurol 2017;16:976–986.
    1. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25:1256–1264.
    1. Biesecker G, Gomez CM. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 1989;142:2654–2659.
    1. Conti‐Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116:2843–2854.
    1. Muppidi S, Utsugisawa K, Benatar M, et al. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 2019;60:14–24.
    1. Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology 1999;52:1487–1489.
    1. Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769–772.
    1. Campbell MJ, Swinscow TDV. Statistics at square one, 11th ed Hoboken, NJ: Wiley‐Blackwell, 2009.
    1. Howard JF Jr, Freimer M, O'Brien F, et al. QMG and MG‐ADL correlations: study of eculizumab treatment of myasthenia gravis. Muscle Nerve 2017;56:328–330.
    1. Vissing J, O'Brien F, Wang JJ, et al. Correlation between myasthenia gravis‐activities of daily living (MG‐ADL) and quantitative myasthenia gravis (QMG) assessments of anti‐acetylcholine receptor antibody‐positive refractory generalized myasthenia gravis in the phase 3 REGAIN study. Muscle Nerve 2018;58:E21–E22.
    1. Barnett C, Bril V, Kapral M, et al. Myasthenia gravis impairment index: responsiveness, meaningful change, and relative efficiency. Neurology 2017;89:2357–2364.
    1. Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics 2016;13:118–131.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel